Merck has entered a collaboration with Innervia, a subsidiary of Barcelona-based Inbrain Neuroelectronics, to develop technologies for vagus nerve stimulation.
The companies will develop graphene-based technologies for neurostimulation that could benefit patients with severe chronic neurological diseases affecting their peripheral nervous system.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?